Genetic Alterations in the Phosphoinositide 3-Kinase/Akt Signaling Pathway Confer Sensitivity of Thyroid Cancer Cells to Therapeutic Targeting of Akt and Mammalian Target of Rapamycin

Dingxie Liu, Peng Hou, Zhi Liu, Guojun Wu, and Mingzhao Xing

1Division of Endocrinology and Metabolism, the Johns Hopkins University School of Medicine, Baltimore, Maryland and 2Breast Cancer Program, Karmanos Cancer Institute, Detroit, Michigan

Abstract

We investigated the genotype-dependent therapeutic potential of targeting the phosphoinositide 3-kinase (PI3K)/Akt pathway for thyroid cancer. Proliferation of TPC1, Hth7, FTC133, OCUT1, K1, and BCPAP cells that harbored PI3K/Akt-activating genetic alterations was potently inhibited by the Akt inhibitor perifosine, whereas SW1736, Hth74, WRO, KAT18, and TAD2 cells that harbored no genetic alterations had no or only modest responses. Inhibition of Akt phosphorylation by perifosine was seen in these cells. Genetic-dependent apoptosis was induced by perifosine in cells selectively tested. Similarly, potent inhibition of cell proliferation by the mammalian target of rapamycin (mTOR) inhibitor temsirolimus occurred in virtually all the cells harboring genetic alterations, whereas modest inhibition was seen in some of the cells not harboring genetic alterations. Temsirolimus inhibited the phosphorylation of p70S6K, a substrate of mTOR. Knockdown of Akt1/2 or mTOR by shRNA approach inhibited the proliferation and colony formation of FTC133 and OCUT1 cells that harbored genetic alterations in the PI3K/Akt pathway but had no effect on SW1736 and KAT18 cells that did not. Transfection with PIK3CA mutants greatly sensitized SW1736 cells to perifosine and temsirolimus. Growth of xenograft tumors derived from FTC133 cells but not SW1736 cells in nude mice was dramatically inhibited by perifosine. Thus, this work for the first time shows that genetic alterations in the PI3K/Akt pathway confer thyroid cancer cells addiction to this pathway and their sensitivity to inhibition by targeting Akt and mTOR. This genotype-based targeting of the PI3K/Akt pathway using Akt and mTOR inhibitors may offer an effective therapeutic strategy for thyroid cancer and warrants further studies.

Introduction

The phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway plays a fundamental role in cell growth, proliferation and survival and, when altered, tumorigenesis (1–3). In this signaling, the p110 catalytic subunits of class I PI3Ks, particularly PIK3CA, phosphor-ylate membrane phosphatidylinositols to produce PI(3,4,5)P3, which in turn binds and recruits the serine/threonine kinase Akt to cell membrane for activation by phosphoinositide-dependent protein kinases, particularly PDK1. A novel Akt inhibitor, perifosine, can selectively prevent the recruitment of the Akt pleckstrin homology domain to the membrane and blocks activation of the downstream signaling (4, 5). The PI3K/Akt signaling can also be activated by RET/PTC or Ras. Activated Akt is translocated to the nucleus where it phosphorylates a multitude of downstream targets, leading to changes in cellular functions. An important downstream target of Akt is mammalian target of rapamycin (mTOR), which plays a critical role in mediating the proliferative function of the PI3K/Akt pathway (6). This signaling can be inhibited by specific mTOR inhibitors, such as temsirolimus (CCI-779) that is highly clinically applicable for its improved water solubility and stability compared with rapamycin (7). The signaling of the PI3K/Akt pathway is naturally antagonized by the tumor suppressor gene PTEN product, PTEN, which is a phosphatase that terminates the signaling of this pathway by dephosphorylating PI(3,4,5)P3 (8).

Driven by genetic alterations, the PI3K/Akt pathway is frequently overactivated in human cancers, including thyroid cancer (1, 9, 10). Follicular thyroid cell–derived thyroid cancer is the most common endocrine malignancy. This cancer is classified into differentiated papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC) and the undifferentiated anaplastic thyroid cancer (ATC; ref. 11). PTC and FTC may progress into poorly differentiated thyroid cancer (PDTC). Genetic alterations in the PI3K/Akt pathway are common in thyroid cancer, including the PIK3CA amplification and mutations, Ras mutations, PTEN mutations, and amplifications of some key genes in this pathway (12–18). These genetic alterations are particularly common and important in aggressive thyroid cancers, such as PDTC and ATC (13, 14, 17, 18), which account for most of the incurable and fatal cases of thyroid cancer. Therefore, the PI3K/Akt pathway is a potentially important and effective therapeutic target in thyroid cancer. We propose that the activating genetic alterations in the PI3K/Akt pathway may confer special sensitivity of thyroid cancer cells to inhibition by targeting the pathway, which may form a basis for the development of novel genetic-based therapeutic strategies for this cancer. In the present study, we tested this hypothesis using two clinically applicable inhibitors, perifosine and temsirolimus, as well as the shRNA approach in a large panel of thyroid cancer cell lines for which we characterized the genotypes of the PI3K/Akt pathway.

Materials and Methods

Thyroid cancer cell lines. The thyroid cancer cell lines C643, Hth7, Hth74, and SW1736 were originally from Dr. N.E. Heldin (University of Uppsala, Uppsala, Sweden); KAT18 was from Dr. Kenneth B. Ain (University
of Kentucky Medical Center, Lexington, KY); OCUT1 was from Dr. Naoyoshi Onoda (Osaka City University Graduate School of Medicine, Osaka, Japan); BCPAP was from Dr. Massimo Santoro (University of Federico II, Naples, Italy); K1 was from Dr. David Wynford-Thomas (University of Wales College of Medicine, Cardiff, United Kingdom); WRO-82-1 was from Dr. G. J. F. Juillard (University of California-Los Angeles School of Medicine, Los Angeles, CA); and FTC133 was from Dr. Georg Brabant (University of Manchester, Manchester, United Kingdom). The normal thyroid cell–derived cell line TAD2 was from Dr. Mario Vitale (Universita ` Federico II, Naples, Italy). The TPC1 cell line was provided by Dr. Alan P. Dackiw (Johns Hopkins University, Baltimore, Maryland). These cancer cells have been recently characterized to be distinct thyroid cancer cell lines (19). They were all grown at 37°C in RPMI 1640 with 10% fetal bovine serum, except for FTC133 that was cultured with DMEM/HAM’S F-12 medium. For some experiments, cells were treated with perifosine or temsirolimus with the indicated concentrations and time, and the medium and agents were replenished every 24 h. Perifosine and temsirolimus were obtained from Cayman Chemical, dissolved in DMSO and ethanol, respectively, with a stock concentration of 10 mM/L, and stored at −20°C.

Analysis of genetic alterations in the PI3K/Akt pathway in thyroid cancer cell lines. We analyzed the major genetic alterations in the PI3K/Akt pathway in all the thyroid cancer cell lines in the present study. *K-Ras* (exons 1 and 2), *N-Ras* (exons 1 and 2), *H-Ras* (exons 1 and 2), *PIK3CA* (exons 9 and 20), and *PTEN* (exons 5–7) were analyzed for mutations using our previously designed primers (14, 18). For genomic DNA amplification of all the genes by PCR, after 4 min of initial denaturing at 95°C, the reaction mixture was run for 35 cycles at 94°C, 54°C, and 72°C, each for 30 s for denaturing, annealing, and elongation, respectively, followed by an elongation at 72°C for 7 min. Copy number of five genes involved in this pathway, including *PIK3CA*, *PIK3CB*, *PDK1*, Akt-1, and Akt-2, which could be functionally important if amplified, was analyzed using the primers and quantitative real-time PCR conditions described previously (18).

Western blotting analysis. Cells were lysed in the radioimmunoprecipitation assay buffer. Cellular proteins were resolved on denaturing polyacrylamide gels, transferred to polyvinylidene difluoride membranes (Amersham Pharmacia Biotech), and blotted with appropriate primary antibodies. Anti–phospho-Akt (Sc-7985-R) and anti–phospho-p70 S6 Kinase (p70S6K; Sc-7985-R), and anti-actin (Sc-16116-R) were purchased from Santa Cruz. Anti–Akt-1 (*2967), anti–Akt-2 (*2964), and anti-mTOR (*2972) were purchased from Cell Signaling Technologies, Inc. Antibody against V5-tag (Amersham Pharmacia Biotech), and blotted with appropriate primary antibodies. Polyacrylamide gels, transferred to polyvinylidene difluoride membranes were visualized using the chemilucent enhanced chemiluminescence detection system (Amersham Pharmacia Biotech).

Lentivector, shRNA plasmid construction, and cell infection with lentivirus. The lentivector pShiro-PGK-puro (Addgene, Inc.), originally constructed as describe (20), was used to express the hairpin RNA specifically against Akt 1/2 (Akt-1 and Akt-2) or mTOR. The oligonucleotide sequences cloned into the vector were as follows. Oligonucleotides simultaneously targeting an identical region of Akt-1/2: sense, 5′-TGT GGT CAT GTA CGA GAT TCG TGA AGA TGA TGT CTT GAA TCT GAC TCT GCC TTT CTT C-3′; antisense, 5′-TGT AGC AGA AAA AAG TGG TCA TGT ACG AGA TGA TCT CTT GAA TCT GTC GCA TGA CCA CCA CA-3′. Oligonucleotides targeting mTOR: sense, 5′-TGT AGC CGC AAT GAG GAA ACT TCA AGA GAT TGG TCA TCT GCC TTT CTT TTT TTT C-3′; antisense, 5′-TGC AGA AAA AAA AAG CCG CAG TGA TGA AAG TCG TCT CTT GAA GTT TCA TCC CGG CTC TA. The annealed double-stranded oligonucleotides were cloned into the Hpa I and Xhol I sites of pShiro-PGK-puro. To generate lentiviral particles, human embryonic kidney 293 cells (American Type Culture Collection) were cotransfected with the lentivector and compatible packaging plasmid mixture using Lipofectamine 2000 (Invitrogen), and the supernatant containing lentivirus was collected 48 h after transfection. For virus infection, cells were exposed to lentivirus-containing supernatant for 24 h in the presence of Polybrene (Sigma). After selection with puromycin for 1 to 2 wk, stable cell pools were used for cell proliferation and colony formation studies.

Cell proliferation assay. Cells (800/well) were seeded into 96-well plates and cultured under various indicated conditions. MTT assay was performed daily over a 5-d time course to evaluate cell proliferation. After 5 d of treatments as indicated, cell culture was added with 10 μL of 5 mg/mL MTT agent (Sigma) and incubated for 4 h, followed by addition of 100 μL of 10% SDS solution and a further incubation overnight. The plates were then read on a microplate reader using the test wavelength of 570 nm and the reference wavelength of 670 nm. Three duplicates were done to determine each data point. IC50 values were calculated using the Reed-Muench method (21).

Morphologic assay for apoptosis. For morphologic examination of apoptotic changes, cells were fixed with 4% paraformaldehyde for 15 min, and then stained with 5 μg/mL Hoechst 33342 for 20 min. After PBS washing, the stained cells were observed under a fluorescence microscope. For quantitation of the number of apoptotic cells, 500 cells were counted under microscope as described in (22), and cells with chromatin condensation, margination or nuclear fragmentation were regarded as apoptotic cells, which are the characteristic morphology of apoptotic nucleus (23).

Colony formation assay. For soft-agar colony-formation assay, 2 × 103 cells (for FTC133) or 5 × 103 (for KAT18) were plated into 12-well plates with a bottom layer of 0.6% agar and a top layer of 0.3% agar. Following the hardening of soft agar, plates were incubated at 37°C with 5% CO2. After 2 to 3 wk of culture, colonies were counted and photographed under a microscope. All the experiments in this study were similarly performed two to four times.

 Xenograft tumor assay in nude mice. FTC133 (2 × 105) or SW1736 (8 × 103) cells were injected s.c. into flanks of nude mice at the age of 4 wk (Harlan Sprague-Dawley). When tumors grew to ∼5 mm in diameter, animals were grouped into two groups (four mice per group) that have similar average tumor size. The two groups were treated daily with the vehicle PBS or 25 mg/kg Perifosine through i.p. injection. Mice were weighed and tumor volume measured at the start of the treatment and twice a week during the course of the therapy. Tumor volumes were calculated by the formula width2 × length/2 as described previously (24). After treatment for 2 wk, tumors were harvested and weighed. The two-tailed Independent-sample t test was used for statistical analysis of differences in tumor volumes and weights between groups.

Results

Characterization of genetic alterations in the PI3K/Akt pathway in thyroid cancer cell lines. We analyzed the genetic alterations in the major components of PI3K/Akt pathway in the thyroid cancer cell lines used in this study. As summarized in Table 1, TPC1, C643, and Hth7 cells harbored RET/PTC1 rearrangement, *H-Ras* mutation, and *N-Ras* mutation, respectively. OCUT1 and K1 harbored *PI3KCA* mutations. It was previously shown that the FTC133 had one *PTEN* allele deleted and the remaining allele harbored a splice variant IVS4-19G→A (25). Here, we also found that this cell line harbored a mutation in the remaining allele of *PTEN* that led to the formation of a premature stop codon in exon 5. Copy number analysis of the *PIK3CA*, *PIK3CB*, *PDK1*, Akt-1, and Akt-2 genes showed only Akt-1 copy gain in Hth7 and BCPAP cells. The remaining five cell lines, SW1736, KAT18, Hth7, WRO, and TAD2, did not harbor any of these genetic alterations in the present study. These results on genetic alterations in thyroid cancer cell lines are consistent with our and other’s previous findings in tumor tissues that these are the major genetic alterations in the Pi3K/Akt pathway in thyroid cancer (12–18). These cell lines constituted a valuable cell model for testing the genetic-dependent inhibition of thyroid cancer cells in the subsequent experiments of this study.

Genetic-selective inhibition of thyroid cancer cell proliferation by the Akt inhibitor perifosine. We examined the
concentration response and time course of the effects of perifosine on PI3K/Akt signaling in FTC133 cells in which PTEN is deficient. As shown in Fig. 1A, inhibition of Akt phosphorylation was remarkable at 0.2 μmol/L and nearly complete at 1 μmol/L. Complete inhibition was observed at 6 h with perifosine at 5 μmol/L and the inhibitory effect remained for at least 24 h (Fig. 1A). We also tested the effect of the Akt inhibitor on other cell lines. As shown in Fig. 1B, at 5 μmol/L, perifosine remarkably inhibited Akt phosphorylation in the seven thyroid cancer cell lines that harbored genetic alternations in the PI3K/Akt pathway, including TPC1, C643, Hth7, FTC133 (again), OCUT1, K1, and BCPAP cells, suggesting that the basal activities of the PI3K/Akt signaling was highly dependent on the genetic alterations in these cells. Perifosine had varying inhibitory effects on Akt phosphorylation in the remaining five cell lines, SW1736, KAT18, Hth74, WRO, and TAD2 cells, which did not harbor these genetic alterations, suggesting that the dependence of the PI3K/Akt signaling on such genetic alterations in these cells might not be as high.

We next examined the effect of perifosine on the proliferation of these cell lines. As shown in Fig. 2A, we found that perifosine significantly inhibited proliferation of TPC1, C643, Hth7, FTC133, OCUT1, K1, and BCPAP cells in a concentration-dependent manner. The cell lines and their sensitivity to the Akt inhibitor perifosine and the mTOR inhibitor temsirolimus are shown in Table 1.

### Table 1. Genotypes of thyroid cancer cell lines and their sensitivity to the Akt inhibitor perifosine and the mTOR inhibitor temsirolimus

<table>
<thead>
<tr>
<th>Cell lines</th>
<th>TPC1</th>
<th>C643</th>
<th>Hth7</th>
<th>FTC133</th>
<th>OCUT1</th>
<th>K1</th>
<th>BCPAP</th>
<th>SW1736</th>
<th>KAT18</th>
<th>Hth74</th>
<th>WRO</th>
<th>TAD2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Derived from PTC, ATC, or FTC</td>
<td>PTC</td>
<td>ATC</td>
<td>ATC</td>
<td>FTC</td>
<td>ATC</td>
<td>PTC</td>
<td>PTC</td>
<td>ATC</td>
<td>ATC</td>
<td>ATC</td>
<td>ATC</td>
<td>ATC</td>
</tr>
<tr>
<td>Genetic alterations</td>
<td>RET/PTC1 rearrangement</td>
<td>H-Ras (G13R&lt;sup&gt;÷&lt;/sup&gt;/G13R&lt;sup&gt;÷&lt;/sup&gt;)</td>
<td>N-Ras (Q61R&lt;sup&gt;÷&lt;/sup&gt;/Q61R&lt;sup&gt;÷&lt;/sup&gt;)</td>
<td>PIK3CA (H1047R&lt;sup&gt;÷&lt;/sup&gt;/H1047R&lt;sup&gt;÷&lt;/sup&gt;)</td>
<td>Akt1 copy gain</td>
<td>PIK3CA (E542K&lt;sup&gt;÷&lt;/sup&gt;/E542K&lt;sup&gt;÷&lt;/sup&gt;)</td>
<td>Akt1 copy gain</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>IC&lt;sub&gt;50&lt;/sub&gt; of perifosine (μmol/L)</td>
<td>3.58</td>
<td>4.47</td>
<td>4.02</td>
<td>1.71</td>
<td>2.17</td>
<td>10.17</td>
<td>4.92</td>
<td>35.49</td>
<td>&gt;1,000</td>
<td>&gt;1,000</td>
<td>&gt;1,000</td>
<td>&gt;1,000</td>
</tr>
<tr>
<td>IC&lt;sub&gt;50&lt;/sub&gt; of temsirolimus (nmol/L)</td>
<td>0.11</td>
<td>0.64</td>
<td>3.98</td>
<td>0.01</td>
<td>7.33</td>
<td>0.01</td>
<td>110.46</td>
<td>&gt;1,000</td>
<td>44.55</td>
<td>18.9</td>
<td>0.20</td>
<td>458.74</td>
</tr>
</tbody>
</table>

NOTE: Ras, PIK3CA, and PTEN were analyzed for mutations, and PIK3CA, PIK3CB, PDK1, Akt-1, and Akt-2 were analyzed for copy number as described in Material and Methods. +/-, heterozygous mutation; +/+, homozygous mutation. The IC<sub>50</sub> values were calculated using the Reed-Muench method (21).

Figure 1. Effects of the Akt inhibitor perifosine and the mTOR inhibitor temsirolimus on the PI3K/Akt signaling in thyroid cancer cells. A, time- and concentration-dependent effects of perifosine and temsirolimus on the PI3K/Akt signaling in the thyroid cancer cell line FTC133. The drug concentrations and time for treatment are as indicated. B, effects of perifosine and temsirolimus in various other thyroid cancer cell lines. As indicated, cells were treated with 5 μmol/L perifosine (top) or 5 nmol/L temsirolimus (bottom) for 24 h. The phosphorylation level of Akt or p70S6K was detected by Western blotting using specific anti-phosphorylated Akt (p-Akt) or p70S6K (p-p70S6K) antibodies. Immunoblotting with antibody against β-actin was used for quality control.
Figure 2. Genetic-selective inhibition of thyroid cancer cell growth by the Akt inhibitor perifosine and mTOR inhibitor temsirolimus. Cells were treated with the indicated concentrations of perifosine (A) or temsirolimus (B) for 5 d with the culture medium and the drug replenished every 24 h, followed by MTT assay to evaluate cell growth. IC_{50} values of the two drugs for each cell line were calculated according to the Reed-Muench method (21).
manner, with IC_{50} values ranging from 1.71 to 10.71 μmol/L (Table 1). These seven cell lines all harbored genetic alterations in the PI3K/Akt pathway (Table 1). The PTEN-deficient cell FTC133 was the most sensitive to perifosine among the seven cell lines, suggesting that homozygous inactivation of the PTEN gene probably had the most profound activating effect on the PI3K/Akt pathway. In contrast, SW1736, KAT18, Hth74, and WRO cells that did not harbor genetic alterations in the PI3K/Akt pathway were not as sensitive to perifosine (Fig. 2A); the IC_{50} value was 35.49 μmol/L for the SW1736 cell and >1,000 μmol/L for KAT18, and Hth74, and WRO cells (Table 1). As expected, the normal thyroid cell–derived TAD2 cell line that lacked PI3K/Akt pathway–associated genetic alterations did not respond well to perifosine (Table 1; Fig. 2A).

Genetic-selective inhibition of thyroid cancer cell proliferation by the mTOR inhibitor temsirolimus. To further explore the important role of genetic alterations in drug sensitivity in the therapeutic targeting of the PI3K/Akt pathway in thyroid cancer cells, we examined the effect of the mTOR inhibitor, temsirolimus, on the proliferation of the 12 thyroid cell lines. The inhibitory effects of temsirolimus on the phosphorylation of p70S6K, a substrate of mTOR that is involved in protein synthesis and cell cycle control (26), were also concentration and time dependent (Fig. 1A). At 5 nmol/L, temsirolimus remarkably suppressed p70S6K phosphorylation in the 12 cell lines (Fig. 1B).

We next examined the inhibitory effects of temsirolimus on the proliferation of the 12 cell lines, which, as illustrated in Fig. 2B, showed a generally similar inhibitory pattern as perifosine did with few exceptions. Specifically, except for BCPAP cell that showed a modest sensitivity, all the other six cells that harbored genetic alterations in the PI3K/Akt pathway were potently sensitive to the inhibition by temsirolimus, with IC_{50} values ranging from 0.01 to 7.33 nmol/L (Table 1). The lower sensitivity of BCPAP cells to temsirolimus may suggest a weak strength of Akt amplification in these seven cell lines all harbored genetic alterations in the PI3K/Akt pathway by specific knockdown of Akt or mTOR. Four thyroid cancer cell lines, including FTC133, OCUT1, SW1736, and KAT18, were chosen for these experiments. In FTC133 cells, transient knockdown of Akt-1 or Akt-2 individually by siRNA partially suppressed cell proliferation and colony formation, and knockdown of both Akt-1 and Akt-2 resulted in a synergistic and remarkable inhibitory effect (data not shown). As Akt-1 and Akt-2 were the most abundant and important isoforms of Akt in thyroid cancer (27), we chose to knock down the two isoforms (Akt-1/2) simultaneously for stable transfection experiments. With this approach, we were able to knock down Akt-1/2 in all the four cell lines with corresponding down-regulation of p-Akt (Fig. 3A). Knockdown of Akt-1/2 inhibited proliferation of FTC133 and OCUT1 cells, but not SW1736 and KAT18 cells (Fig. 3C). Similarly, partial knockdown of mTOR partially inhibited proliferation of FTC133 and OCUT1 cells but not SW1736 and KAT18 cells (Fig. 3C). These results were consistent with the genetic-dependent effects of perifosine and temsirolimus on thyroid cancer cells (Table 1; Fig. 2).

Genetic-selective inhibition of cell colony formation by siRNA targeting PI3K/Akt pathway. We also investigated the effects of stable knockdown of Akt-1/2 or mTOR on colony formation of FTC133, OCUT1, SW1736, and KAT18 cells in soft agar (i.e., anchorage-independent cell growth), a characteristic feature of cellular transformation. As shown in Supplementary Fig. S1A, colony formation of FTC133 and OCUT1 cells, but not as much SW1736 and KAT18 cells, was inhibited by Akt-1/2 knockdown, in both colony number and size. Similarly, mTOR knockdown significantly inhibited the colony formation of FTC133 and OCUT1 cells but not SW1736 and KAT18 cells (Supplementary Fig. S1A). Supplementary Fig. S1B illustrates more clearly the differential effects of knockdown of Akt-1/2 or mTOR on the colony formation of the four cells. These results showed the importance of genetic alterations of the PI3K/Akt pathway in maintaining the malignant and transformed state of thyroid cancer cells, further supporting the potential effectiveness of genetic-selective therapy of drugs targeting the PI3K/Akt pathway for thyroid cancer.

Expression of mutant PIK3CA increased the sensitivity of SW1736 cells to perifosine and temsirolimus. We next tested whether introduction of mutant PIK3CA into thyroid cancer cells that did not harbor genetic alterations in PI3K/Akt pathway could increase the sensitivity of cells to perifosine and temsirolimus. Two PIK3CA mutants, including H1047R and E545K that are the most common mutations of PIK3CA found in human cancer and showed strong oncogenic effects when transfected in breast cell lines (28), were used to transfect SW1736 cells. Fig. 4A and B shows stable expression of exogenous PIK3CA mutants and the corresponding increase in p-Akt level in cells transfected with the PIK3CA mutants. The proliferation of cells transfected with PIK3CA mutants was more potently inhibited by perifosine and temsirolimus than the cells transfected with control vector (Fig. 4C). For cells transfected with vector, H1047R and E545K, the IC_{50} values of perifosine were 30.55, 4.26, and 6.14 μmol/L, respectively, and IC_{50} values of temsirolimus were >1,000, 3.57, and 10.52 μmol/L, respectively.

Genetic-selective induction of thyroid cancer cell apoptosis and inhibition of xenograft tumor growth by the Akt inhibitor perifosine. To investigate whether genetic-dependent effects of perifosine and temsirolimus on cell growth involved cell death, we examined proapoptotic effects of the two inhibitors on thyroid cancer cell lines using nuclear morphologic analysis as described in Material and Methods. After treatment with perifosine, chromatin condensation, margination and nuclear fragmentation, which are characteristic morphologies of apoptotic nuclear (23), were frequently observed in FTC133 and OCUT1 cells that harbored genetic alterations in the PI3K/Akt pathway but not in SW1736 and KAT18 cells that did not (Fig. 5A). The apoptotic cell number increased >20-fold in the former two cells, whereas it only minimally increased in the latter two cells after treatment with perifosine (Fig. 5B). We did not see effects of temsirolimus on cell apoptosis in these four thyroid cancer cell lines (data not shown).

Because cell apoptosis was an important mechanism in the genetic-dependent inhibition of thyroid cancer cell growth induced by perifosine, perifosine has a potential to be highly effective in treating thyroid cancer in vivo. We therefore next tested the genetic-dependent effect of perifosine on the growth of xenograft thyroid tumors in nude mice. As shown in Fig. 5C, the PTEN-deficient FTC133 cell–derived xenograft tumors progressively grew in the
control group, whereas the tumors stopped growing or even shrank in perifosine-treated group. At the end of the experiment after a 2-week treatment, the tumor volumes and weights were $1.807 \pm 0.774 \text{cm}^3$ (control group) versus $0.177 \pm 0.095 \text{cm}^3$ (perifosine group; $P = 0.005$) and $1.567 \pm 0.265 \text{g}$ (control group) versus $0.198 \pm 0.051 \text{g}$ (perifosine group; $P < 0.001$), respectively (Fig. 5C). In contrast, perifosine only had a minimal inhibitory effect on the growth of SW1736-derived xenograft tumors that did not harbor genetic alterations in the PI3K/Akt pathway (Fig. 5D). At the end of the experiment after a 2-week treatment, the tumor volumes and weights were $0.449 \pm 0.121 \text{cm}^3$ (control group) versus $0.315 \pm 0.160 \text{cm}^3$ (perifosine group) and $0.355 \pm 0.115 \text{g}$ (control group) versus $0.270 \pm 0.149 \text{g}$ (perifosine group), respectively (Fig. 5D).

**Discussion**

Thyroid cancer is the most common endocrine malignancy with a rapidly increasing incidence in recent decades (29–31), posing an increasing challenge to the treatment of this cancer. Although surgical and radiodine treatments are generally effective, many thyroid cancer patients have persistent or recurrent disease that is currently incurable and associated with increased morbidity and mortality. PDTC and ATC, which can derive from PTC and FTC or develop de novo, are particularly difficult to treat (32, 33). In fact, ATC is one of the most aggressive and deadly human cancers. New therapies are needed for incurable thyroid cancers. The recent several clinical trials on receptor tyrosine kinase inhibitors in thyroid cancers are promising but the results are still limited at this stage (34–36). More effective molecular-targeted therapeutic strategies need to be developed based on molecular mechanisms, particularly the derangements in major signaling pathways, in thyroid cancer.

The PI3K/Akt pathway is a well-explored therapeutic target in human cancers (2, 3, 37). Given the important role of the PI3K/Akt pathway and its common genetic alterations in thyroid cancer (1, 9, 10, 38), in the present study, we tested the therapeutic potential of
targeting this pathway, with a focus on its genotype dependence and the potential of using genetic alterations in this pathway to predict the sensitivity of thyroid cancer cells. Various inhibitors targeting this pathway have been developed for therapeutic testing. Among these are the Akt inhibitors and mTOR inhibitors, which target two key steps, Akt and mTOR, respectively in this pathway. The Akt inhibitor perifosine and mTOR inhibitor temsirolimus are among the most promising inhibitors, which have been or are being actively tested in clinical trials and have shown acceptable toxicity profiles and great promises in some cancers (4, 5, 39, 40). They were therefore specifically tested in the present study.

We showed a striking dependency of perifosine and temsirolimus, particularly the former, on genetic alterations in the PI3K/Akt pathway in the inhibition of thyroid cancer cells. Specific knockdown of Akt and mTOR using shRNA approaches showed identical genetic dependence patterns in inhibiting the proliferation and anchorage-independent colony formation of thyroid cancer cells. Moreover, transfection of cells with PIK3CA mutants conferred increased sensitivity to perifosine and temsirolimus in cells that did not naturally harbor genetic alterations in the PI3K/Akt pathway. These results suggest that the results obtained with drug inhibitors were indeed genetic-specific. The one exception that showed inconsistent genetic-dependent pattern was the WRO cell, which did not harbor genetic alterations at or upstream of Akt in the PI3K/Akt pathway and, as expected, was highly resistant to the Akt inhibitor perifosine, but was highly sensitive to the mTOR inhibitor temsirolimus. It is likely that an uncharacterized Akt-independent mechanism played a major role in the activation of mTOR signaling in this cell as shown in other cancer cells (41). This mechanism might also occur in the Hth74 cell that did not harbor genetic alterations in the PI3K/Akt pathway and was highly resistant to perifosine but was fairly well sensitive to temsirolimus.

The results in the present study also suggest that thyroid cancer cells are highly additive to the PI3K/Akt signaling when genetic alterations in this pathway are present, similar to breast cancer cells (42, 43) and lung cancer cells (44). It is important to note that the PI3K/Akt-associated genetic alterations tested in the present study, such as PIK3CA, Ras, and PTEN mutations and PIK3CA amplifications, are particularly common in aggressive thyroid cancers, such as PTC and FTC (13, 14, 17, 18, 19). Therefore, genetic-based targeting of the PI3K/Akt pathway using perifosine or temsirolimus may be a particularly promising therapeutic strategy for these therapeutically challenging thyroid cancers. It is worth noting that the dramatic inhibition of cell proliferation was achieved in cells harboring genetic alterations with perifosine at the WRO cell, which did not harbor genetic alterations at or upstream of Akt in the PI3K/Akt pathway and, as expected, was highly resistant to the Akt inhibitor perifosine, but was highly sensitive to the mTOR inhibitor temsirolimus. It is likely that an uncharacterized Akt-independent mechanism played a major role in the activation of mTOR signaling in this cell as shown in other cancer cells (41). This mechanism might also occur in the Hth74 cell that did not harbor genetic alterations in the PI3K/Akt pathway and was highly resistant to perifosine but was fairly well sensitive to temsirolimus.

The results in the present study also suggest that thyroid cancer cells are highly additive to the PI3K/Akt signaling when genetic alterations in this pathway are present, similar to breast cancer cells (42, 43) and lung cancer cells (44). It is important to note that the PI3K/Akt-associated genetic alterations tested in the present study, such as PIK3CA, Ras, and PTEN mutations and PIK3CA amplifications, are particularly common in aggressive thyroid cancers, such as PTC and FTC (13, 14, 17, 18). Therefore, genetic-based targeting of the PI3K/Akt pathway using perifosine or temsirolimus may be a particularly promising therapeutic strategy for these therapeutically challenging thyroid cancers. It is worth noting that the dramatic inhibition of cell proliferation was achieved in cells harboring genetic alterations with perifosine at the WRO cell, which did not harbor genetic alterations at or upstream of Akt in the PI3K/Akt pathway and, as expected, was highly resistant to the Akt inhibitor perifosine, but was highly sensitive to the mTOR inhibitor temsirolimus. It is likely that an uncharacterized Akt-independent mechanism played a major role in the activation of mTOR signaling in this cell as shown in other cancer cells (41). This mechanism might also occur in the Hth74 cell that did not harbor genetic alterations in the PI3K/Akt pathway and was highly resistant to perifosine but was fairly well sensitive to temsirolimus.

The results in the present study also suggest that thyroid cancer cells are highly additive to the PI3K/Akt signaling when genetic alterations in this pathway are present, similar to breast cancer cells (42, 43) and lung cancer cells (44). It is important to note that the PI3K/Akt-associated genetic alterations tested in the present study, such as PIK3CA, Ras, and PTEN mutations and PIK3CA amplifications, are particularly common in aggressive thyroid cancers, such as PTC and FTC (13, 14, 17, 18). Therefore, genetic-based targeting of the PI3K/Akt pathway using perifosine or temsirolimus may be a particularly promising therapeutic strategy for these therapeutically challenging thyroid cancers. It is worth noting that the dramatic inhibition of cell proliferation was achieved in cells harboring genetic alterations with perifosine at the WRO cell, which did not harbor genetic alterations at or upstream of Akt in the PI3K/Akt pathway and, as expected, was highly resistant to the Akt inhibitor perifosine, but was highly sensitive to the mTOR inhibitor temsirolimus. It is likely that an uncharacterized Akt-independent mechanism played a major role in the activation of mTOR signaling in this cell as shown in other cancer cells (41). This mechanism might also occur in the Hth74 cell that did not harbor genetic alterations in the PI3K/Akt pathway and was highly resistant to perifosine but was fairly well sensitive to temsirolimus.
the concentrations around 5 to 10 \( \mu \text{mol/L} \), which was within the clinically achievable and safe peak plasma concentration ranges (i.e., 10–15 \( \mu \text{mol/L} \); refs. 45, 46). The potency of temsirolimus in the sensitive cells was extremely high, with IC\(_{50}\) in the nanomolar range, consistent with previous findings that temsirolimus at the nanomolar range effectively suppressed the growth of cancer cells (47). Because cell apoptosis was a major mechanism in genetic-dependent inhibition of thyroid cancer cells by perifosine, this inhibitor may have a particularly high clinical potential for effective treatment of thyroid cancer, as supported by its profound genetic-dependent inhibitory effect on the growth of xenograft thyroid tumors.

In summary, we have shown that genetic alterations in the PI3K/Akt pathway confer strong sensitivity of thyroid cancer cells to inhibition by targeting Akt or mTOR. It may thus be possible to use genetic markers in the PI3K/Akt pathway to predict the responses of thyroid cancer to specific inhibitors of this pathway.

Given the common genetic alterations in the PI3K/Akt pathway in thyroid cancer, particularly aggressive and incurable types, perifosine and temsirolimus, which have well shown acceptable clinical profiles, are highly promising in genetic-targeted therapies for thyroid cancer.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**Acknowledgments**

Received 3/23/09; revised 6/23/09; accepted 7/8/09; published OnlineFirst 8/25/09.

**Grant support:** NIH R01 grant CA113507-01 (M. Xing).

The costs of publication of this article were defrayed in part by the payment of page charges. This article therefore must hereby be marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Drs. N.E. Heldin, K.B. Ain, N. Onoda, M. Santoro, D. Wynford-Thomas, G. Brabant, A.P. Dackiw, G.J. Juillard, M. Vitale, R.E. Schweppe, and B.R. Haugen for kindly providing us or facilitating the accessibility to the cell lines used in this study.

**Figure 5.** Genetic-selective induction of thyroid cancer cell apoptosis and inhibition of the xenograft thyroid tumor growth by the Akt inhibitor perifosine.  
A, representative morphology of cell nuclei after treatment with or without perifosine. Cells were treated with 5 \( \mu \text{mol/L} \) perifosine for 48 h and apoptotic cells were determined by Hoechst 33342 staining. Cells were observed under a fluorescent microscope and selective apoptotic nuclei are indicated with arrows, showing chromatin margination, condensation, and fragmentation, which are characteristics of apoptosis. B, quantitation of the number of apoptotic cells by examining 500 cells under a fluorescent microscope for each sample. C, effects of perifosine on the growth of xenograft tumor derived from FTC133 cells. Left, the time course of tumor growth, measured as the average tumor volume in each group at the indicated time of treatment with vehicle (PBS) or perifosine, 25 mg/kg/d peritoneally. Points, mean of the values obtained from four mice in each group; bars, SD. Right, FTC133-derived tumor weights from the four individual mice in each group after a 2-wk treatment. Animals were finally sacrificed and xenograft tumors were surgically removed and weighted. Short horizontal bar, the average weight of the tumors from each group. \( P \) values were obtained by independent-sample \( t \) test. D, effects of perifosine on the growth of SW1736-derived xenograft tumor. The experimental procedures were identical as described for FTC133 cell–derived tumors.
References

Correction: Genetic Alterations in the Phosphoinositide 3-Kinase/Akt Signaling Pathway Confer Sensitivity of Thyroid Cancer Cells to Therapeutic Targeting of Akt and Mammalian Target of Rapamycin

In this article (Cancer Res 2009;69:7311–9) which was published in the September 15, 2009 issue of Cancer Research (1), all of the concentration units reported in Fig. 2B and the right panel of Fig. 4C should be nmol/L, not μmol/L. Also, the right panel of Fig. 4C is missing the last bar, which should represent the growth of SW1736 cells transfected with E545K PIK3CA and treated with temsirolimus at the concentration point of 40 nmol/L. The value represented by this missing bar is 49.5, which has been counted in the calculation of the IC\textsubscript{50} value of temsirolimus.


©2009 American Association for Cancer Research.
doi:10.1158/0008-5472.CAN-09-20-COR3
Genetic Alterations in the Phosphoinositide 3-Kinase/Akt Signaling Pathway Confer Sensitivity of Thyroid Cancer Cells to Therapeutic Targeting of Akt and Mammalian Target of Rapamycin

Dingxie Liu, Peng Hou, Zhi Liu, et al.


Updated version

Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-09-1077

Supplementary Material

Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2009/08/24/0008-5472.CAN-09-1077.DC1

Cited articles

This article cites 45 articles, 13 of which you can access for free at:
http://cancerres.aacrjournals.org/content/69/18/7311.full.html#ref-list-1

Citing articles

This article has been cited by 7 HighWire-hosted articles. Access the articles at:
/content/69/18/7311.full.html#related-urls

E-mail alerts

Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions

To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.